Literature DB >> 29764526

Cannabinoid signalling in embryonic and adult neurogenesis: possible implications for psychiatric and neurological disorders.

Rúbia W de Oliveira1, Cilene L Oliveira2, Francisco S Guimarães3, Alline C Campos3.   

Abstract

Cannabinoid signalling modulates several aspects of brain function, including the generation and survival of neurons during embryonic and adult periods. The present review intended to summarise evidence supporting a role for the endocannabinoid system on the control of neurogenesis and neurogenesis-dependent functions. Studies reporting participation of cannabinoids on the regulation of any step of neurogenesis and the effects of cannabinoid compounds on animal models possessing neurogenesis-dependent features were selected from Medline. Qualitative evaluation of the selected studies indicated that activation of cannabinoid receptors may change neurogenesis in embryonic or adult nervous systems alongside rescue of phenotypes in animal models of different psychiatric and neurological disorders. The text offers an overview on the effects of cannabinoids on central nervous system development and the possible links with psychiatric and neurological disorders such as anxiety, depression, schizophrenia, brain ischaemia/stroke and Alzheimer's disease. An understanding of the mechanisms by which cannabinoid signalling influences developmental and adult neurogenesis will help foster the development of new therapeutic strategies for neurodevelopmental, psychiatric and neurological disorders.

Entities:  

Keywords:  cannabinoids; neurogenesis; neurology; psychiatric disorders

Mesh:

Substances:

Year:  2018        PMID: 29764526     DOI: 10.1017/neu.2018.11

Source DB:  PubMed          Journal:  Acta Neuropsychiatr        ISSN: 0924-2708            Impact factor:   3.403


  6 in total

1.  A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial).

Authors:  Cheney J G Drew; Mark Postans; Cateno Petralia; Rachel McNamara; Philip Pallmann; Dave Gillespie; Lisa H Evans; Nils Muhlert; Mia Winter; Khalid Hamandi; William P Gray
Journal:  Pilot Feasibility Stud       Date:  2019-07-06

2.  The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.

Authors:  Xiangjuan Kong; Qingshan Miao; Xiaozi Lu; Zeng Zhang; Min Chen; Jinxiang Zhang; Jinguo Zhai
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Divergence and Convergence of Cerebral Ischemia Pathways Profile Deciphers Differential Pure Additive and Synergistic Mechanisms.

Authors:  Penglu Wei; Pengqian Wang; Bing Li; Hao Gu; Jun Liu; Zhong Wang
Journal:  Front Pharmacol       Date:  2020-02-25       Impact factor: 5.810

Review 4.  A Guide to Targeting the Endocannabinoid System in Drug Design.

Authors:  Adam Stasiulewicz; Katarzyna Znajdek; Monika Grudzień; Tomasz Pawiński; And Joanna I Sulkowska
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

Review 5.  Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?

Authors:  Tomasz Charytoniuk; Hubert Zywno; Karolina Konstantynowicz-Nowicka; Klaudia Berk; Wiktor Bzdega; Adrian Chabowski
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

Review 6.  Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy.

Authors:  Diogo M Lourenço; Leonor Ribeiro-Rodrigues; Ana M Sebastião; Maria J Diógenes; Sara Xapelli
Journal:  Int J Mol Sci       Date:  2020-10-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.